Novartis' Starlix approved for Type II diabetes

The FDA granted marketing approval to Novartis (NVS; SWX:NOVN) for its Starlix nateglinide, a D-phenylalanine derivative, to treat Type II diabetes as monotherapy and in combination with metformin. Th...